Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Just revisiting this chat after many years lol this dead? or still chance for revival?
Companies House shows the company as dissolved https://find-and-update.company-information.service.gov.uk/company/05315929
This has to be one of the worst companies on AIM, sucked in so much people in the hype a couple of years back and investors lost so much money. To top it off after all this time, my local plumber makes more money then this public listed company, maybe we should get him to list on the AIM market too.
Thanks Zap, sorry not been update to date with stuff, 50p? what was the consolidation ratio? as it closed at 0.06.
what is everyone's prediction on the opening price?
Not sure why your getting defensive, I've been a shareholder for a while now. Have you ever run a business before? there is no reason for a company like this to be overdue and handle stuff the way they have over the last year.
Why would a company like this not submit their accounts on time? just hope their not looking to fold.
AIM really is a joke, falling with good news. I'm probably going to stop investing when I've reached my targets.
Excellent News!!
WTH happened here? I remember I was going to invest when this share was hyped up @ 80-90p per share. How did it come to this?
How come this share don't show up on iii board??
how far can it go??
thanks mogo guess I will stay away for a bit, Have you looked into TYM or SRB?
WWOOW... just thought I would check on this share, I had some a few years ago, what made it drop ssoo low? thinking of buying some at these prices or this a dead duck?
YORK-based drug analysis firm Avacta today revealed that it had achieved success in the North American market. Avacta announced that its newly appointed sales and marketing partner for Optim in North America, Pall Corporation, has secured its first Optim sale, to one of the 10 largest pharmaceutical companies in the US. Optim allows drug developers to gain vital information about compounds using tiny samples, more cheaply and quickly than other methods. Pall Life Sciences was appointed as distributor for North America in February. Pall has been working with Avacta to generate new sales leads for Optim and has also been developing the US sales pipeline that Avacta had grown before the distribution agreement was signed. In a statement, Avacta said: “In the short period since Pall’s appointment, the Optim sales pipeline in the US has doubled following successful marketing events. Avacta has completed the first phase of training for Pall’s sales and support teams and Pall has now closed its first sale to one of the largest global pharmaceutical companies.” Alastair Smith, the chief executive of Avacta Group, said: “The US is the major market for Optim and I am delighted with the energetic and proactive start that Pall has made as our commercial partner in North America. “The urgency with which the Pall team has undertaken sales and support training, the successful delivery of marketing events that have had a positive impact on the number of sales leads and the closing of the first sale following a trial of the instrument by the customer, is very encouraging. “Today’s order means we have already met the target of 12 Optim sales in the current year. I look forward to reporting on further sales in due course and on the wider development of the commercial relationship with Pall.”
rising now...